



EHA2021 abstracts:

What's hot in acute lymphoblastic leukemia?

To help navigate the exciting content being presented at the EHA 2021 Virtual Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.



Click
the abstracts
to view



Scientific Education Support

Top abstracts to look out for at EHA 2021

Abstract	Title	Speaker
S107	<u>BRUTON'S TYROSINE KINASE INHIBITION SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA TO ASPARAGINASE BY INTERFERING WITH THE AMINO ACID RESPONSE - A ROLE FOR C-MYC</u>	Miriam Butler
S111	<u>REDEFINING LOW RISK HIGH HYPERDIPLOIDY IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA</u>	Anthony Moorman
S112	<u>UPDATED RESULTS OF THE GIMEMA LAL2116, D-ALBA TRIAL, FOR NEWLY DIAGNOSED ADULTS WITH PH+ ALL</u>	Sabina Chiaretti
S113	<u>INTERIM RESULTS OF A PHASE II STUDY OF BLINATUMOMAB PLUS PONATINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Nicholas Short
S114	<u>PRELIMINARY RESULTS OF THE GIMEMA LAL2317 SEQUENTIAL CHEMOTHERAPY-BLINATUMOMAB FRONT-LINE TRIAL FOR NEWLY DIAGNOSED ADULT PH-NEGATIVE B-LINEAGE ALL PATIENTS</u>	Renato Bassan
S115	<u>DONOR-DERIVED CD7 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Jing Pan
S117	<u>PHASE 2 RESULTS OF THE ZUMA-3 STUDY EVALUATING KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Bijal D. Shah



Abstract	Title	Speaker
S240	<u>PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASE INHIBITORS POST-ALLOGENEIC STEM CELL TRANSPLANTATION IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SUBANALYSIS OF GITMO PH-POSITIVE ALL STUDY</u>	Anna Candoni
EP341	<u>ZUMA-4 PHASE 1 LONG-TERM RESULTS: KTE-X19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PEDIATRIC/ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Alan S. Wayne
EP350	<u>CHARACTERISTICS AND OUTCOME OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND COVID 19 INFECTION IN THE FIRST VS. SECOND EPIDEMIC WAVE IN SPAIN: A STUDY FROM THE PETHEMA AND GETH GROUPS</u>	Josep Maria Ribera
EP351	<u>FAVORABLE OUTCOMES AFTER NOVEL THERAPIES FOR RELAPSE/REFRACTORY PHILADELPHIA-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Ibrahim Aldoss
EP364	<u>OUTCOME OF RELAPSED OR REFRACTORY ACUTE B-LYMPHOBLASTIC LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE RECEIVING INOTUZUMAB OZOGAMICIN</u>	Sabine Kayser
EP367	<u>A PHASE II STUDY OF BLINATUMOMAB FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA</u>	Nicholas Short
EP1228	<u>SURVIVAL TRENDS OF ADULT PATIENTS WITH RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OVER 20 YEARS: AN ALWP-EBMT ANALYSIS</u>	Ali Bazarbachi





Follow us on Twitter to keep up to date
with the latest from the EHA 2021 Virtual
Congress!

@ALL_Hub_
#EHA2021
lymphoblastic-hub.com



Scientific Education Support